We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,
Australasia,Asia,Middle East,Africa
Monthly Production Capacity: hundreds of grams
Packaging Information: 500mg,1g, 10g,50g 100g per package with icebag
Delivery Lead Time: In stock or 2-3 weeks
Sample Provided: yes
Payment Terms: T/T
Apelin is the endogenous ligand of the transmembrane G protein-coupled receptor APJ, which is widely distributed in tissues and expressed in cardiovascular, kidney, nerve and brain systems. The Apelin/APJ system has multiple biological effects such as enhancing myocardial contractility, lowering blood pressure, promoting blood vessel growth, regulating insulin secretion, pituitary hormone release and body fluid balance. Apelin precursor peptide consists of 77 amino acid residues, which are then cleaved into fragments of different amino acid lengths, including: Apelin-12, Apelin-13, Apelin-17 and Apelin-36, etc. These peptides can be produced by peptide synthesis . Studies have shown that Apelin-17 can promote platelet aggregation and promote in vitro thrombosis, while APJ receptor blocker F13A inhibits Apelin-17-induced platelet aggregation and in vitro thrombosis. In addition, Apelin-17 has a synergistic platelet activator thrombin-induced platelet aggregation.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
